266 related articles for article (PubMed ID: 21947448)
1. Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors.
Mao Y; Li Y; Hao M; Zhang S; Ai C
J Mol Model; 2012 May; 18(5):2185-98. PubMed ID: 21947448
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR analysis of a series of S-DABO derivatives as anti-HIV agents by CoMFA and CoMSIA.
Xu HR; Fu L; Zhan P; Liu XY
SAR QSAR Environ Res; 2016 Dec; 27(12):999-1014. PubMed ID: 27667445
[TBL] [Abstract][Full Text] [Related]
3. The development of HEPT-type HIV non-nucleoside reverse transcriptase inhibitors and its implications for DABO family.
Chen W; Zhan P; Wu J; Li Z; Liu X
Curr Pharm Des; 2012; 18(27):4165-86. PubMed ID: 22621244
[TBL] [Abstract][Full Text] [Related]
4. Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase.
D'Cruz OJ; Uckun FM
J Enzyme Inhib Med Chem; 2006 Aug; 21(4):329-50. PubMed ID: 17059165
[TBL] [Abstract][Full Text] [Related]
5. HEPT derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase: QSAR studies agree with the crystal structures.
Gaudio AC; Montanari CA
J Comput Aided Mol Des; 2002 Apr; 16(4):287-95. PubMed ID: 12400858
[TBL] [Abstract][Full Text] [Related]
6. Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant.
Ragno R; Mai A; Sbardella G; Artico M; Massa S; Musiu C; Mura M; Marturana F; Cadeddu A; La Colla P
J Med Chem; 2004 Feb; 47(4):928-34. PubMed ID: 14761194
[TBL] [Abstract][Full Text] [Related]
7. Molecular docking and 3D-QSAR studies on triazolinone and pyridazinone, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
Sivan SK; Manga V
J Mol Model; 2010 Jun; 16(6):1169-78. PubMed ID: 20013136
[TBL] [Abstract][Full Text] [Related]
8. Docking-based 3D-QSAR analyses of pyrazole derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
Cichero E; Fossa P
J Mol Model; 2012 Apr; 18(4):1573-82. PubMed ID: 21805124
[TBL] [Abstract][Full Text] [Related]
9. Docking-based CoMFA and CoMSIA studies on naphthyl-substituted diarylpyrimidines as NNRTIs.
Wu HQ; Yao J; He QQ; Chen FE
SAR QSAR Environ Res; 2014; 25(10):761-75. PubMed ID: 25242254
[TBL] [Abstract][Full Text] [Related]
10. A 3D QSAR study of a series of HEPT analogues: the influence of conformational mobility on HIV-1 reverse transcriptase inhibition.
Kireev DB; Chrétien JR; Grierson DS; Monneret C
J Med Chem; 1997 Dec; 40(26):4257-64. PubMed ID: 9435895
[TBL] [Abstract][Full Text] [Related]
11. Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors.
Liu G; Wang W; Wan Y; Ju X; Gu S
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29751616
[TBL] [Abstract][Full Text] [Related]
12. Artificial neural networks: non-linear QSAR studies of HEPT derivatives as HIV-1 reverse transcriptase inhibitors.
Douali L; Villemin D; Zyad A; Cherqaoui D
Mol Divers; 2004; 8(1):1-8. PubMed ID: 14964783
[TBL] [Abstract][Full Text] [Related]
13. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
[TBL] [Abstract][Full Text] [Related]
14. Non-nucleoside HIV-1 reverse transcriptase inhibitors, Part 7. Synthesis, antiviral activity, and 3D-QSAR investigations of novel 6-(1-naphthoyl) HEPT analogues.
Ji L; Chen FE; Feng XQ; De Clercq E; Balzarini J; Pannecouque C
Chem Pharm Bull (Tokyo); 2006 Sep; 54(9):1248-53. PubMed ID: 16946529
[TBL] [Abstract][Full Text] [Related]
15. QSAR for anti-HIV activity of HEPT derivatives.
Bazoui H; Zahouily M; Boulajaaj S; Sebti S; Zakarya D
SAR QSAR Environ Res; 2002 Oct; 13(6):567-77. PubMed ID: 12479372
[TBL] [Abstract][Full Text] [Related]
16. N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Mitchell ML; Son JC; Lee IY; Lee CK; Kim HS; Guo H; Wang J; Hayes J; Wang M; Paul A; Lansdon EB; Chen JM; Eisenberg G; Geleziunas R; Xu L; Kim CU
Bioorg Med Chem Lett; 2010 Mar; 20(5):1585-8. PubMed ID: 20137928
[TBL] [Abstract][Full Text] [Related]
17. Hologram quantitative structure-activity relationships investigations of non-nucleoside reverse transcriptase inhibitors.
Pungpo P; Hannongbua S; Wolschann P
Curr Med Chem; 2003 Sep; 10(17):1661-77. PubMed ID: 12871115
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: SAR and Lead Optimization Using CoMFA and CoMSIA Studies (1995-2016).
Vanangamudi M; Poongavanam V; Namasivayam V
Curr Med Chem; 2017 Nov; 24(34):3774-3812. PubMed ID: 28685686
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR and docking studies on the HEPT derivatives of HIV-1 reverse transcriptase.
Latha RS; Vijayaraj R; Singam ER; Chitra K; Subramanian V
Chem Biol Drug Des; 2011 Sep; 78(3):418-26. PubMed ID: 21689378
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Mai A; Sbardella G; Artico M; Ragno R; Massa S; Novellino E; Greco G; Lavecchia A; Musiu C; La Colla M; Murgioni C; La Colla P; Loddo R
J Med Chem; 2001 Aug; 44(16):2544-54. PubMed ID: 11472208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]